Breaking News, Collaborations & Alliances

BioMed X and Daiichi Sankyo Launch Immuno-Oncology Research Team

The new research team will work on multispecific biologics to target innovative pathways in the tumor microenvironment (TME).

Author Image

By: Charlie Sternberg

Associate Editor

BioMed X, an innovation hub for pharma, has introduced a new research team at its Heidelberg institute for multispecific biologics in the field of immuno-oncology in collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute in Munich. This new project, led by BioMed X boot camp winner Dr. Reda Benmebarek, will explore next-generation biologics as a potential strategy to transform how solid tumors are treated. “The ability of multispecific biologics to engage multiple tar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics